

Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

ACC 2012 Publication Schedule / Conference Call Details

Ladies and Gentlemen,

Findings from the Phase III EINSTEIN-PE study will be presented in the Late-Breaking Clinical Trials Session on Monday, March 26th, 2012, 08:00 – 09:30 a.m. CDT, at the American College of Cardiology's 61st Annual Scientific Sessions (ACC) in Chicago, USA, by lead investigator Harry R. Buller, MD, Academic Medical Center, Amsterdam, the Netherlands. We cordially invite investors and analysts to participate in our conference call on this occasion.

The schedule is as follows:

Monday **March 26, 2012**	**Internet address for all information material and webcast:** www.investor.bayer.com / www.investor.bayer.de
	Press release on Rivaroxaban data presented at the ACC conference
05:00 p.m. CEST	**Investor Conference Call to discuss findings from the Phase III EINSTEIN-PE study of Rivaroxaban presented at ACC** with Dr. Kemal Malik, Head of Global Development at Bayer Healthcare Pharmaceuticals, Dr. Frank Misselwitz, Head Therapeutic Area Cardiovascular and Coagulation, Global Clinical Development Dr. Alexander Rosar, Head of Investor Relations
	Dial-in Numbers **International: +44 203 059 8128** **UK: 0203 059 8128** **US: 1 855 272 3513** **Germany: 069 566 036 000** If you are unable to participate in the conference, a recording will be available for access by touch tone telephone until March 29, 2012. A live audio broadcast (English only) will be available on the internet.
	Replay Dial-in Numbers **International: +44 121 260 4861, Passcode: 25017#** **UK: 0121 260 4861, Passcode: 25017#** **US: 646 200 5850, Passcode: 25017#** **Germany: 069 710 488 70, Passcode: 25017#**
08:00 p.m. CEST	On-demand version of the conference call webcast available on the internet.

CEST = Central European Summer Time = Greenwich Mean Time (GMT) +2 hours;
CDT = Central Daylight Time = Greenwich Mean Time (GMT) -5 hours;

Best regards,
Bayer Investor Relations